Z

    Zevra Therapeutics Inc. (ZVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.74
    +0.18 (+1.51%)

    Market Cap: $686.77M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -5.26%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.18
    Range$0.13 - $0.21
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$0.20+11.3%
    60d ago$0.18+0.0%
    30d ago$0.18+0.0%
    7d ago$0.18+1.4%
    Current$0.18
    Revenue Consensus
    $37M
    Range$35M - $41M
    9 analysts
    Dec 31, 2026
    EPS Consensus$0.70
    Range$0.60 - $0.83
    4 analysts
    Revenue Consensus
    $47M
    Range$44M - $54M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.70---
    Sep 26EST
    		-$0.18---
    Jun 26
    		$0.25$0.08+212.50%Beat+516.7%
    Mar 26
    		$0.18$0.08+125.00%Beat+400.0%
    Dec 25
    		$0.19$0.05+280.00%Beat+127.5%
    Sep 25
    		$-0.01N/A+75.00%Beat+98.6%
    Jun 25
    		$-0.06N/A-104.35%Miss+87.5%
    Mar 25
    		$-0.06N/A+66.67%Beat+85.0%
    Dec 24
    		$-0.69$-0.40-73.11%Miss-72.5%
    Sep 24
    		$-0.69$-0.41-68.29%Miss-72.5%
    Jun 24
    		$-0.48$-0.44-9.09%Miss-220.0%
    Mar 24
    		$-0.40$-0.48+16.67%Beat-17.6%
    Dec 23
    		$-0.40$-0.27-48.15%Miss-53.8%
    Sep 23
    		$-0.40$-0.30-33.33%Miss-110.5%
    Jun 23
    		$-0.15N/A+55.88%Beat+78.6%
    Mar 23
    		$-0.34$-0.23-47.83%Miss-580.0%
    Dec 22
    		$-0.26$-0.17-52.94%Miss-225.0%
    Sep 22
    		$-0.19$-0.10-90.00%Miss-280.0%
    Jun 22
    		$-0.70$-0.14-400.00%Miss-75.0%
    Mar 22
    		$-0.05$-0.05+0.00%Beat+96.9%
    Dec 21
    		$-0.08$-0.07-14.29%Miss+92.5%
    Sep 21
    		$-0.05$-0.08+37.50%Beat+92.2%
    Jun 21
    		$-0.40$0.23-273.91%Miss-350.0%
    Mar 21
    		$-1.61$-0.17-847.06%Miss+16.1%
    Dec 20
    		$-1.07$-0.64-67.19%Miss-568.8%
    Sep 20
    		$-0.64$-0.80+20.00%Beat-166.7%
    Jun 20
    		$0.16$-0.02+900.00%Beat+103.0%
    Mar 20
    		$-1.92$-1.76-9.09%Miss+73.9%
    Dec 19
    		$-0.16N/A+88.24%Beat+95.0%
    Sep 19
    		$0.96N/A+121.43%Beat+107.2%
    Jun 19
    		$-5.28$-6.80+22.35%Beat+49.2%
    Mar 19
    		$-7.36$-7.36+0.00%Beat+74.0%
    Dec 18
    		$-3.20N/A+57.89%Beat+72.2%
    Sep 18
    		$-13.41$-12.32-8.85%Miss-23.3%
    Jun 18
    		$-10.40$-15.42+32.56%Beat-47.7%
    Mar 18
    		$-28.32$-11.04-156.52%Miss-110.7%
    Dec 17
    		$-11.52$-10.96-5.11%Miss-5.9%
    Sep 17
    		$-10.88$-10.76-1.12%Miss+4.2%
    Jun 17
    		$-7.04$-10.08+30.16%Beat-
    Mar 17
    		$-13.44$-10.24-31.25%Miss-
    Dec 16
    		$-10.88$-11.15+2.42%Beat-
    Sep 16
    		$-11.36$-10.03-13.26%Miss-

    Key Metrics

    Valuation
    P/E Ratio19.25EV/EBITDA6.32x
    Price/FCF21.33xFCF Yield4.69%
    Profitability
    Profit Margin42.80%Operating Margin42.30%
    ROE34.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-39.45x
    Current Ratio5.17xQuick Ratio5.12x
    Trading Statistics
    Beta0.92Avg Volume952.14K
    52-Week High$15.0452-Week Low$7.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.80
    SMA 20$11.54
    SMA 50$12.09
    SMA 200$10.22
    EMA 10$11.70
    EMA 20$11.62
    EMA 50$11.66
    EMA 200$10.70

    MACD

    Line: 0.05Signal: -0.01Hist: 0.06

    ADX

    ADX: 13.5+DI: 21.2-DI: 23.5

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down16.0
    PSAR$11.23

    Bollinger Bands

    Upper Band$12.39
    Lower Band$10.69
    %B Position1472%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    51.5

    Momentum Oscillators

    Stoch %K66.3
    Stoch %D69.2
    Williams %R-32.1
    ROC (10d)1.8%
    Momentum0.21
    CCI (20d)27.5
    MFI (14d)47.0

    Volatility Measures

    ATR (14d)$0.49(4.2%)
    StdDev (20d)0.42
    Hist Vol57.5%(High)

    Volume Flow

    VWAP$11.65
    OBV39.1M
    AD Line21.1M
    CMF (20d)0.169

    Volume Metrics

    Avg Vol (20d)912.1K
    Vol Ratio0.9x
    VWMA (20d)$11.55

    Pivot Points

    R3$11.99
    R2$11.89
    R1$11.73
    Pivot Point$11.63
    S1$11.47
    S2$11.38
    S3$11.21

    Advanced Oscillators

    TSI2.19
    Ultimate Osc53.3
    KST18.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$39.66M$36.22M$34.13M$26.06M$25.88M$20.40M$12.04M$3.69M$4.45M$3.42M$12.92M$2.90M
    Cost of Revenue$0$1.90M$1.52M$1.24M$0$1.34M$1.37M$2.30M$3.57M$175,000$1.23M$144,000
    Gross Profit$39.66M$34.32M$32.60M$24.82M$25.88M$19.06M$10.68M$1.39M$876,000$3.25M$11.69M$2.75M
    Operating Expenses$22.89M$-17,823,000$23.29M$20.68M$96.92M$24.42M$26.09M$28.70M$24.67M$23.74M$26.85M$18.11M
    R&D$4.49M$4.39M$2.62M$3.43M$3.43M$3.26M$8.35M$10.95M$10.52M$12.28M$11.42M$12.30M
    SG&A$16.56M$20.78M$20.35M$16.93M$20.78M$19.55M$16.13M$16.21M$12.60M$9.93M$14.66M$5.82M
    Operating Income$16.78M$52.15M$9.31M$4.14M$-71,039,000$-5,362,000$-15,416,000$-27,306,000$-23,795,000$-20,486,000$-15,157,000$-15,364,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-2,565,000$878,000$236,000$-262,000$-369,000$1.43M$2.27M$1.26M$1.84M$-194,000$548,000$-1,372,000
    Income Before Tax$12.79M$44.80M$12.67M$-977,000$76.91M$-1,917,000$-20,368,000$-33,225,000$-19,855,000$-16,692,000$-19,892,000$-10,190,000
    Income Tax Expense$4.04M$6.91M$501,000$-433,000$2.20M$1.18M$15.37M$0$70,000$-70,000$0$177,000
    Net Income$8.75M$37.89M$12.16M$-544,000$74.71M$-3,099,000$-35,739,000$-33,225,000$-19,925,000$-16,622,000$-19,892,000$-10,367,000
    EBITDA$10.00M$45.43M$12.41M$-2,058,000$77.43M$853,000$-17,343,000$-30,345,000$-16,453,000$-15,324,000$-18,557,000$-11,500,000
    EBIT$10.23M$45.68M$12.90M$-1,239,000$76.54M$-491,000$-18,101,000$-31,962,000$-18,015,000$-16,886,000$-19,344,000$-11,562,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ZVRA

    News

    Zevra Therapeutics to Present New Long-Term Real-World Data

    Zevra Therapeutics announced the presentation of new long-term real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC) at the SSIEM Annual Symposium. The data, from U.S. and German early access programs, highlights sustained disease stabilization and a consistent safety profile across diverse NPC patient populations over several years. This reinforces the drug's effectiveness and safety, with some patients experiencing rapid clinical deterioration upon discontinuation.

    GlobeNewswire•8/25/26•
    Bullish

    A rare-disease drug has up to 8 years of real-world data. Zevra will present the findings.

    Zevra Therapeutics will present new long-term real-world data on MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) at the 2026 SSIEM Annual Symposium. The data, including up to 8 years of experience from U.S. expanded access and German compassionate use programs, show sustained disease stabilization across various patient populations and ages. MIPLYFFA is FDA-approved in the U.S. and has an EMA Marketing Authorization Application under review, with findings emphasizing its long-term safety and effectiveness in treating NPC.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    Zevra Therapeutics to Present New Long-Term Real-World Data

    Zevra Therapeutics announced the presentation of new long-term real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC) at the SSIEM Annual Symposium. The data, from U.S. and German early access programs, highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations over up to eight years of treatment. The presentations reinforce MIPLYFFA's effectiveness and safety, even noting clinical deterioration in patients who discontinued treatment.

    GlobeNewswire•8/25/26•
    Bullish

    ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?

    Zevra Therapeutics (ZVRA) shares rallied 8% to a near five-year high after positive brokerage actions and the company's request to add a new patent for its Miplyffa drug to the FDA's Orange Book. Analysts from Citizens and Canaccord raised their price targets, citing extended market exclusivity for Miplyffa, which generated over 80% of Zevra's sales in 2025. Retail sentiment for ZVRA also turned "extremely bullish" on Stocktwits, with users predicting further price increases.

    Stocktwits•8/25/26•
    Bullish

    Zevra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Zevra Therapeutics announced inducement grants of stock options to two new non-executive employees. These grants were made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The options have a ten-year term and vest over four years, subject to continued employment.

    Moomoo•8/22/26•
    Neutral

    Frequently Asked Questions About ZVRA

    Does ZVRA pay dividends?
    Zevra Therapeutics Inc. (ZVRA) does not currently pay a regular dividend.
    What is ZVRA's P/E ratio?
    Zevra Therapeutics Inc. has a price-to-earnings (P/E) ratio of 19.25.
    What is ZVRA's market cap?
    Zevra Therapeutics Inc. (ZVRA) has a market capitalization of $686.77M with a current stock price of $11.74.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In